What Endocrinologists Wish GLP-1 Patients Knew
Endocrinologists are the metabolic specialists. Here are the insights they most want their GLP-1 patients to understand.
Medical Disclaimer: This article reflects common expert opinions and does not replace individual medical advice from your healthcare provider.
Endocrinologists specialize in hormones and metabolism. They were among the first specialists to prescribe GLP-1 medications and have deep experience with these drugs. Here is what they wish every patient knew before starting semaglutide or tirzepatide.
1. Obesity Is a Chronic Disease, Not a Willpower Failure
The single most important message: obesity is a neuroendocrine disease involving dozens of hormones, neural pathways, and genetic factors. GLP-1 medications treat the biology. Stopping them is like stopping blood pressure medication - the underlying condition does not go away.
2. Get Your Labs Monitored
GLP-1 medications affect multiple metabolic systems. Regular lab work helps track benefits and catch issues early:
- Thyroid (TSH): GLP-1 medications carry a theoretical thyroid cancer risk (seen in rodents). Monitor thyroid function
- Kidney function: Dehydration from reduced intake can affect kidney function
- Liver enzymes: Track fatty liver improvement
- A1C: Monitor glucose metabolism changes even if you are not diabetic
- Nutritional markers: B12, iron, vitamin D can decline with reduced food intake
3. Weight Is Not the Only Metric
Endocrinologists evaluate treatment success by metabolic health markers, not just the scale. Improvements in blood pressure, A1C, lipids, liver enzymes, and inflammatory markers are equally or more important than pounds lost.
4. Slow Titration Is Better
Rushing to the highest dose increases side effects without improving long-term outcomes. Endocrinologists prefer finding the minimum effective dose: the lowest dose that produces meaningful weight loss with tolerable side effects.
5. Plan for Long-Term Treatment
The evidence is clear: most patients regain weight after stopping GLP-1 medications. Plan financially and mentally for ongoing treatment. Some patients can reduce to a maintenance dose, but few can stop entirely without significant regain.
6. Your Other Medications May Need Adjustment
As you lose weight and metabolic health improves, blood pressure medications, diabetes medications, and cholesterol medications may need to be reduced. Do not adjust other medications without consulting your prescribing provider.
Frequently Asked Questions
Do endocrinologists support GLP-1 for weight loss?
Most endocrinologists strongly support GLP-1 medications for appropriate patients. The Endocrine Society has published guidelines endorsing pharmacotherapy for obesity. The main frustrations endocrinologists express are about access, cost, and patients stopping treatment prematurely.
What lab work should I get on GLP-1?
Endocrinologists recommend baseline and periodic monitoring of: thyroid function (TSH), kidney function (BMP), liver enzymes (ALT/AST), lipid panel, A1C or fasting glucose, vitamin D, B12, and iron/ferritin. Frequency depends on your health status and response to treatment.
Should I see an endocrinologist for GLP-1?
Not necessarily. Primary care providers and telehealth clinicians can prescribe and manage GLP-1 medications for most patients. An endocrinologist referral is recommended if you have complex metabolic disease, thyroid concerns, diabetes requiring insulin management, or are not responding as expected.
What is the biggest mistake GLP-1 patients make?
According to endocrinologists: stopping the medication because they 'reached their goal weight.' Obesity is a chronic condition, and most patients need ongoing treatment to maintain weight loss. Stopping leads to weight regain in the majority of patients within 1-2 years.
Expert-Guided GLP-1 Treatment
Trimi clinicians follow evidence-based protocols informed by endocrinology best practices.
Get Started TodayMore on Expert Advice
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).